Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NeOnc Technologies Holdings, Inc.

NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Tickers NTHI
NeOnc Technologies Holdings, Inc. Joins Russell Microcap® Index
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Tickers NTHI
NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Tickers NTHI
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Tickers NTHI
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Tickers NTHI
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Tickers NTHI
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Tickers NTHI
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Tickers NTHI
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Tickers NTHI
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Tickers NTHI
NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of Directors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Receives Pharma Tech Outlook’s Top Drug Delivery Platform Award for 2024
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Wins California Investment Forum’s Breakthrough Medical Technology Achievement Award
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Holdings Receives FDA Authorization to Proceed with Phase 1/2 Trials of NEO212 for Primary Brain Tumors and for Brain Metastasis in Combination with Standard of Care Therapy
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Formalizes Exclusive Global IP Licensing Agreement with USC for Enhanced Method of Delivering Novel Pharma Therapeutics to the Brain
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Appoints Sidra Medicine CEO and Forbes Top 100 Healthcare Leader, Dr. Iyabo Tinubu-Karch, to Scientific Advisory Board
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.